Results 81 to 90 of about 25,648 (169)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress

Journal of Experimental & Clinical Cancer Research
Background Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and a salvage therapy for relapsed/refractory patients who have been treated with intensive chemotherapy.
Jenna L. Carter, Yongwei Su, Eman T. Al-Antary, Jianlei Zhao, Xinan Qiao, Guan Wang, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Steven A. Buck, Maik Hüttemann, Joshua E. Allen, Varun V. Prabhu, Jay Yang, Jeffrey W. Taub, Yubin Ge   +17 more
doaj   +1 more source

A case of hypocalcemia, hypophosphatemia and hypomagnesemia in association with Venetoclax

Turkish Journal of Internal Medicine
Venetoclax is a drug commonly associated with tumor lysis syndrome (TLS) and electrolyte imbalances. However, its effects on electrolyte metabolism are not limited to TLS.
Tuğcan Alp Kırkızlar
doaj   +1 more source

Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study

Therapeutic Advances in Hematology
Background: The response rate of traditional first-line induction chemotherapy (IC) for newly diagnosed acute myeloid leukemia needs to be improved, but it is not clear whether adding venetoclax or hypomethylating agents (HMAs) to IC will improve the ...
Fangfei Xu, Kuangguo Zhou, Duanhao Gong, Wei Huang   +3 more
doaj   +1 more source

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models [PDF]

, 2016

core   +1 more source

Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report. [PDF]

SAGE Open Med Case Rep
Benallaoua K, Lacoeuilhe P, Gendrot B, Muhammad S, Fouquet G.   +4 more
europepmc   +1 more source

Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. [PDF]

Cancer
Perrone S, De Fazio L, Monachetti S, Molica M.   +3 more
europepmc   +1 more source

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy [PDF]

, 2018
Coats, Josh, Collins, Graham P., Cross, Matthew, Dyer, Martin J. S., Eyre, Toby A., Follows, George, Fox, Christopher P., Hodson, Andrew, Iyengar, Sunil, Morley, Nick, Narat, Santosh, Walter, Harriet S.   +11 more
core   +3 more sources

Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma. [PDF]

Clin Exp Med
Shi Y, Wen H, Cao T, Zhao Y, Xu Y, Sun J, Zheng X, Jin J, Tong H, Xie W.   +9 more
europepmc   +1 more source

Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in Combination with Senescence-Inducing Chemotherapy. [PDF]

J Clin Med
Saleh T, Ramadan M, Alsoud A, Al Shboul S.   +3 more
europepmc   +1 more source

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia [PDF]

, 2017
C. J. Owen, C. L. Toze, C. Shustik, I. Bence-Bruckler, R. Delage, S. Coutre   +5 more
core   +1 more source